US equities
|
NVDA
$239.96
▲+2.57%
SPCX
$169.77
▲+6.80%
MU
$1,063.65
▼-1.05%
TSLA
$379.71
▲+2.46%
SNDK
$1,706.49
▼-0.78%
MSFT
$528.85
▲+2.19%
INTC
$116.18
▼-2.64%
META
$743.07
▲+2.06%
NVDA
$239.96
▲+2.57%
SPCX
$169.77
▲+6.80%
MU
$1,063.65
▼-1.05%
TSLA
$379.71
▲+2.46%
SNDK
$1,706.49
▼-0.78%
MSFT
$528.85
▲+2.19%
INTC
$116.18
▼-2.64%
META
$743.07
▲+2.06%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Altamira Therapeutics Ltd. - Common Shares
(NQ:
CYTO
)
0.3001
UNCHANGED
Last Price
Updated: 3:55 PM EST, Dec 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altamira Therapeutics Ltd. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference
May 19, 2022
HAMILTON, BERMUDA / ACCESSWIRE / May 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Issues Shareholder Letter
May 18, 2022
Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd....
From
Altamira Therapeutics
Via
AccessWire
Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia
May 05, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Altamira Therapeutics
Via
AccessWire
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19
April 19, 2022
HAMILTON, BERMUDA / ACCESSWIRE / April 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Earnings Scheduled For March 10, 2022
↗
March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...
Via
Benzinga
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results
April 12, 2022
- Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern. - Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliver -...
From
Altamira Therapeutics
Via
AccessWire
Why Altamira Therapeutics Stock Is Soaring
↗
April 11, 2022
Altamira Therapeutics Ltd (NASDAQ: CYTO) shares are trading higher Monday after the company announced a peer-reviewed publication on positive in vitro data with its Bentrio...
Via
Benzinga
Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant
April 11, 2022
Study Confirms in vitro Efficacy / Safety of Bentrio(TM) for Delta Variant - Prophylactic treatment of human nasal mucosa with Bentrio™ was reported to significantly reduce the viral titer vs. controls...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics FY 2021 Earnings Conference Call On April 12, 2022 At 08:00 AM ET
↗
April 04, 2022
Altamira Therapeutics (NASDAQ:CYTO) will host a conference call at 08:00 AM ET on April 12, 2022, to discuss FY 2021 earnings results. How to Attend Altamira Therapeutics (CYTO) Conference Call Follow...
Via
Benzinga
Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET
April 04, 2022
HAMILTON, BERMUDA / ACCESSWIRE / April 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it...
From
Altamira Therapeutics
Via
AccessWire
Topics
Earnings
Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio
March 15, 2022
HAMILTON, BERMUDA / ACCESSWIRE / March 15, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Orphazyme Shares Plunge
↗
March 11, 2022
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq dropping 150 points on Friday. The Dow traded up 0.07% to 33,198.82 while the NASDAQ fell 1.18% to 12,...
Via
Benzinga
Why Are Altamira Therapeutics Shares Gaining Today?
↗
March 11, 2022
Altamira Therapeutics Ltd (NASDAQ: CYTO) shares are surging after announcing preclinical efficacy data from testing its Bentrio nasal spray against the omicron...
Via
Benzinga
95 Biggest Movers From Friday
↗
March 14, 2022
Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9....
Via
Benzinga
Mid-Day Market Update: Gold Down 1%; Clearside Biomedical Shares Jump
↗
March 11, 2022
U.S. stocks traded mixed midway through trading, with the Nasdaq dropping around 100 points on Friday. The Dow traded up 0.49% to 33,336.14 while the NASDAQ fell 0.73% to 13,032....
Via
Benzinga
50 Stocks Moving In Friday's Mid-Day Session
↗
March 11, 2022
Gainers Marygold Companies (NYSE: MGLD) jumped 189.4% to $6.28 after dropping 21% on Thursday. Altamira Therapeutics Ltd. (NASDAQ: CYTO) shares rose 63.5% to $1.13....
Via
Benzinga
Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant
March 11, 2022
HAMILTON, BERMUDA / ACCESSWIRE / March 11, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
30 Stocks Moving in Friday's Pre-Market Session
↗
March 11, 2022
Gainers Excellon Resources Inc. (NYSE: EXN) rose 133.7% to $2.29 in pre-market trading after jumping around 13% on Thursday. Marygold Companies (NYSE: MGLD) rose 107.4% to...
Via
Benzinga
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19
March 09, 2022
HAMILTON, BERMUDA / ACCESSWIRE / March 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Altamira, Nuance Pharma Ink Licensing Pact For Bentrio In China, Additional Asian Markets
↗
March 04, 2022
Altamira Therapeutics Ltd (NASDAQ: CYTO) has entered into an exclusive licensing and distribution agreement with Nuance Pharma Ltd in the Chinese Mainland...
Via
Benzinga
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
March 04, 2022
- Nuance Pharma to develop and commercialize Bentrio™ nasal spray in Chinese Mainland, Hong Kong, Macau and South Korea - Altamira to receive up to $23.5 million in upfront and milestone payments...
From
Altamira Therapeutics
Via
AccessWire
88 Biggest Movers From Yesterday
↗
March 09, 2022
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) climbed 203.3% to settle at $1.00 on Tuesday. Hycroft recently reported preliminary FY21 operating results. Kala...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
February 15, 2022
Tuesday's session saw 95 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-...
Via
Benzinga
Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo
February 14, 2022
- 75 patients randomized in Part B of study to receive either intranasal betahistine or placebo - Top-line results from the trial expected to be announced in Q2-2022 HAMILTON, BERMUDA / ACCESSWIRE /...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets
February 09, 2022
HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
February 07, 2022
HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Establishes OTC Consumer Health Business Unit
February 04, 2022
- Dedicated unit to support Altamira's activities in consumer health products - OTC Consumer Health to be led by experienced marketing strategist, Jean Lachance HAMILTON, BERMUDA / ACCESSWIRE /...
From
Altamira Therapeutics
Via
AccessWire
Altamira's Bentrio Nasal Spray Approved In Malaysia
↗
January 21, 2022
The Medical Device Authority of Malaysia has approved Altamira Therapeutics Ltd's (NASDAQ: CYTO) Bentrio. "We are very pleased with the swift 'go...
Via
Benzinga
Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia
January 21, 2022
HAMILTON, BERMUDA / ACCESSWIRE / January 21, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Provides Update on RNA Therapeutics Program
January 13, 2022
- Covadonga Pañeda, Ph.D., to join leadership team as Chief Development Officer for RNA therapeutics - Receipt of NIH grant to help advance siRNA delivery platform for use in extrahepatic inflammatory...
From
Altamira Therapeutics
Via
AccessWire
< Previous
1
2
3
4
5
6
7
8
9
Next >
